Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion

Novo Nordisk has agreed to acquire Akero Therapeutics for $54 per share in cash, totaling $4.7 billion, with a potential additional $6 per share contingent value right (CVR) upon U.S. regulatory approval of Akero's lead asset, efruxifermin (EFX), for compensated cirrhosis due to MASH. This strategic acquisition enhances Novo Nordisk's metabolic disease pipeline with EFX, a potentially best-in-class FGF21 analog currently in Phase 3 trials for MASH, building on strong Phase 2b results. While the deal is not expected to impact Novo Nordisk's 2025 operating profit outlook, it will negatively affect 2025 free cash flow by approximately $4 billion and reduce 2026 operating profit growth by around three percentage points due to increased R&D costs, with the transaction being primarily debt-financed.

Analysis

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases. Transaction terms Novo Nordisk will pay $54 per share in cash (or an aggregated value of $4.7 billion) at closing. In addition, Akero shareholders will receive a non-transferable CVR entitling holders to a potential additional payment of $6 per share in cash (or an aggregated value of $0.5 billion) upon U.S. regulatory approval of EFX for the treatment of compensated cirrhosis due to MASH. Strategic And Portfolio Fit The acquisition reflects Novo Nordisk's long-term strategy to develop innovative and differentiated medicines for diabetes, obesity and associated comorbidities. Akero's fibroblast growth factor 21 (FGF21) analog efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). Also Read: Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites EFX is being evaluated as a once-weekly subcutaneous injection in the phase 3 SYNCHRONY program, which consists of three clinical trials designed to support regulatory approval for the treatment of pre-cirrhotic (F2-F3) MASH and compensated cirrhosis (F4) due to MASH. The phase 3 program builds on two 96-week phase 2b trials, in which EFX has been observed to significantly improve liver fibrosis and reverse compensated cirrhosis due to MASH. Over 96 weeks, the HARMONY (F2-F3) and SYMMETRY (F4) trial demonstrated 49% and 29% reduction in fibrosis without worsening of MASH, respectively, compared to 19% and 11% in the respective placebo groups. Financial implications The transaction is not expected to impact Novo Nordisk's previously communicated operating profit outlook for 2025. The free cash flow outlook for 2025 is expected to be negatively impacted by approximately $4 billion, reflecting the expected enterprise value. The implied 2025 free cash flow outlook is therefore 9-19 billion Danish kroner, depending on the timing of closing. For 2026, the acquisition is expected to lead to increased research and development costs, with an estimated negative impact on full-year operating profit growth in 2026 of around three percentage points. The transaction will be mainly debt-financed. Price Action: AKRO stock is up 17.64% at $54.69 during the premarket session at the last check on Thursday. Read Next: Photo: Shutterstock © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Novo Nordisk (NVO) has agreed to acquire Akero Therapeutics (AKRO) for $4.7 billion in cash, or $54 per share, with an additional $0.5 billion contingent on U.S. regulatory approval of EFX for compensated cirrhosis due to MASH. This acquisition aligns with NVO's long-term strategy to expand its portfolio in diabetes, obesity, and associated comorbidities, specifically targeting metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead asset, efruxifermin (EFX), an FGF21 analog, is positioned as a potentially best-in-class treatment for MASH and is currently in Phase 3 clinical trials. EFX demonstrated significant efficacy in Phase 2b trials, showing 49% and 29% fibrosis reduction in F2-F3 and F4 MASH patients, respectively, compared to 19% and 11% in placebo groups over 96 weeks. This robust clinical profile underpins the strategic value of the acquisition for NVO's pipeline. While the transaction is not expected to alter Novo Nordisk's 2025 operating profit outlook, it will negatively impact 2025 free cash flow by approximately $4 billion, reflecting the enterprise value. Furthermore, the acquisition is projected to reduce NVO's full-year operating profit growth in 2026 by around three percentage points due to increased research and development costs, with the deal primarily debt-financed. Akero Therapeutics' stock (AKRO) reacted positively to the news, trading up 17.64% to $54.69 in premarket, indicating market approval of the acquisition price relative to its previous valuation.

Key Decisions for Investors

• Akero Therapeutics shareholders should assess the immediate cash premium against the potential upside of the contingent value right, which is tied to EFX's U.S. regulatory approval for compensated cirrhosis due to MASH.
• Novo Nordisk investors should weigh the strategic long-term pipeline enhancement in the MASH market against the projected near-term negative impact on 2025 free cash flow and 2026 operating profit growth.
• Investors tracking the metabolic disease sector should monitor EFX's Phase 3 trial progress and regulatory milestones, as its potential best-in-class profile could reshape the MASH treatment landscape.